Murray Passo to Infliximab
This is a "connection" page, showing publications Murray Passo has written about Infliximab.
Connection Strength
0.244
-
Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America. Pediatr Rheumatol Online J. 2017 Jun 13; 15(1):50.
Score: 0.140
-
Emerging therapies in juvenile rheumatoid/idiopathic arthritis. Curr Probl Pediatr Adolesc Health Care. 2006 Mar; 36(3):97-103.
Score: 0.064
-
2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. Arthritis Rheumatol. 2019 06; 71(6):864-877.
Score: 0.040